本帖最后由 老马 于 2013-3-13 13:43 编辑
- p( }, L# z3 K- w" B2 c
7 a+ c6 M5 W5 {0 z S: T6 r% a健择（吉西他滨）+顺铂+阿瓦斯汀
- [# d4 B- z+ Q* M Gemzar +Cisplatin + Avastin, L% S+ d$ ^! G# k
http://annonc.oxfordjournals.org/content/21/9/1804.full: h3 y- `3 @% K5 T: _. e
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 7 O, M& B$ x* C' x' Q
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
, Z$ ^( {) r3 a! T: h* t; ?; }Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 5 P- B$ b2 M8 R( l5 T) v+ [
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 249)
8 S# b# n( S. S. |华为网盘附件：$ X4 k9 |' i" E! p8 {7 V- `' \- K
【华为网盘】ava.JPG
! v1 y! R# y; S/ C6 J4 x% W; E! q; h) { |
显身卡
